Figure 6
Cytotoxicity assay. CD3+ T cells from patient 5 were stimulated with WT1-A or WT1A1 peptides twice as described in Figure 5. Target cells used included the ALL derived 697 cell line (A0201+; WT1+) and the B-cell lymphoma cell line SKLY-16 (A0201+; WT1−). The cytotoxicity of the T cells was measured using a standard 51Cr release assay. The SKLY-16 cells pulsed with WT1-A (SKLY-WT1A) or an irrelevant Ewing sarcoma–derived HLA-A0201 binding peptide (SKLY-EW) were used as positive and negative controls for the specificity of killing. Effector/target (E:T) ratios are indicated on the x-axis. Data demonstrate T cell–specific killing against WT1 plus HLA-matched targets.
